EP Patent

EP4164668A1 — Adeno-associated virus vector delivery for muscular dystrophies

Assigned to Nationwide Childrens Hospital Inc · Expires 2023-04-19 · 3y expired

What this patent protects

The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subj…

USPTO Abstract

The disclosure provides method of treating muscular dystrophy in a subject in need comprising administering a gene therapy vector, such as adeno-associated virus (AAV) vector, expressing a miniaturized human micro-dystrophin gene in combination with a step of suppressing the subject's immune system.

Drugs covered by this patent

Patent Metadata

Patent number
EP4164668A1
Jurisdiction
EP
Classification
—
Expires
2023-04-19
Drug substance claim
No
Drug product claim
No
Assignee
Nationwide Childrens Hospital Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.